Hims & Hers Health (NYSE:HIMS) Price Target Raised to $42.00

Hims & Hers Health (NYSE:HIMS) had its target price lifted by Needham & Company LLC from $35.00 to $42.00 in a report issued on Tuesday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Other research analysts have also issued reports about the company. Barclays boosted their price target on Hims & Hers Health from $29.00 to $39.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 17th. Jefferies Financial Group set a $24.50 price objective on Hims & Hers Health in a research report on Tuesday, May 12th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $25.00 target price on shares of Hims & Hers Health in a research note on Tuesday, May 5th. UBS Group set a $23.00 target price on shares of Hims & Hers Health in a report on Friday, May 22nd. Finally, Wall Street Zen lowered shares of Hims & Hers Health from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Four research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Hims & Hers Health presently has a consensus rating of “Hold” and a consensus target price of $32.43.

Hims & Hers Health Stock Performance

Shares of HIMS stock opened at $28.79 on Tuesday. The firm has a market cap of $6.66 billion, a price-to-earnings ratio of -45.70, a PEG ratio of 57.49 and a beta of 2.40. The company’s 50 day moving average is $32.07 and its 200 day moving average is $26.08. The company has a quick ratio of 1.56, a current ratio of 1.69 and a debt-to-equity ratio of 2.18. Hims & Hers Health has a 52-week low of $13.74 and a 52-week high of $65.30.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.32). The business had revenue of $753.21 million during the quarter, compared to the consensus estimate of $698.90 million. Hims & Hers Health had a negative return on equity of 5.89% and a negative net margin of 5.51%.The business’s quarterly revenue was up 38.2% on a year-over-year basis. During the same period last year, the firm earned $0.17 EPS. On average, sell-side analysts anticipate that Hims & Hers Health will post -0.05 EPS for the current fiscal year.

Insider Activity

In related news, COO Michael Chi sold 14,027 shares of the company’s stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $31.50, for a total transaction of $441,850.50. Following the transaction, the chief operating officer directly owned 432,124 shares of the company’s stock, valued at $13,611,906. This represents a 3.14% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Oluyemi Okupe sold 7,163 shares of the company’s stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $36.49, for a total value of $261,377.87. Following the transaction, the chief financial officer directly owned 284,321 shares in the company, valued at $10,374,873.29. This represents a 2.46% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 83,126 shares of company stock worth $2,711,339. Company insiders own 11.76% of the company’s stock.

Institutional Investors Weigh In On Hims & Hers Health

A number of large investors have recently modified their holdings of HIMS. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Hims & Hers Health by 23.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 418,699 shares of the company’s stock valued at $12,373,000 after purchasing an additional 78,543 shares during the last quarter. Geneos Wealth Management Inc. acquired a new position in Hims & Hers Health during the 1st quarter valued at approximately $30,000. EverSource Wealth Advisors LLC raised its holdings in shares of Hims & Hers Health by 273.7% in the second quarter. EverSource Wealth Advisors LLC now owns 938 shares of the company’s stock worth $47,000 after buying an additional 687 shares during the last quarter. Amundi raised its holdings in shares of Hims & Hers Health by 5.3% in the second quarter. Amundi now owns 10,296 shares of the company’s stock worth $489,000 after buying an additional 522 shares during the last quarter. Finally, California Public Employees Retirement System lifted its stake in shares of Hims & Hers Health by 9.5% during the second quarter. California Public Employees Retirement System now owns 338,620 shares of the company’s stock worth $16,880,000 after buying an additional 29,471 shares during the period. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Key Headlines Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims & Hers reported second-quarter revenue of $753.2 million, up 38.2% year over year and ahead of analyst expectations of $698.9 million. Subscriber growth and demand for its health and weight-management offerings remain key growth drivers. Hims & Hers Health Q2 2026 Earnings Call Summary
• Positive Sentiment: The company raised its annual revenue outlook, supporting the long-term growth case. Needham and Bank of America analysts reportedly maintained a more constructive view, suggesting the stock could appreciate as investments in new products and international expansion begin to pay off. Needham analyst outlook
• Neutral Sentiment: Hims plans to introduce certain legally available peptide products in 2026. However, analysts expect the launch to contribute little revenue this year, making it primarily a longer-term growth opportunity. As Hims prepares for peptides launch, Wall Street cautious on prospects this year
• Negative Sentiment: Quarterly EPS came in at a loss of $0.37, substantially below the expected loss of $0.05. The wider loss was linked to the shift toward branded GLP-1 obesity drugs, while gross-margin compression and negative free cash flow raised concerns that faster growth is not translating into improved earnings. Hims & Hers’ Revenue Beat Came With a Profitability Problem
• Negative Sentiment: Citigroup issued a pessimistic outlook, reflecting skepticism about near-term margins and execution. Citigroup forecast
• Negative Sentiment: Multiple law firms announced investigations into possible securities-law violations and alleged fiduciary-duty issues. The inquiries follow an FTC lawsuit concerning alleged data-sharing, billing and cancellation practices, adding legal, reputational and potential financial risks. HIMS shareholder alert

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.